Boston Scientific Co. (NYSE:BSX) Shares Purchased by Victory Capital Management Inc.

Victory Capital Management Inc. increased its holdings in shares of Boston Scientific Co. (NYSE:BSX – Get Rating) by 1.6% in the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 524,244 shares of the medical equipment provider’s stock after purchasing an additional 8,460 shares during the quarter. Victory Capital Management Inc.’s holdings in Boston Scientific were worth $24,246,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also recently bought and sold shares of BSX. International Assets Investment Management LLC acquired a new stake in Boston Scientific during the 1st quarter worth approximately $54,000. Acadian Asset Management LLC acquired a new stake in Boston Scientific in the first quarter valued at approximately $35,000. Prudential PLC acquired a new stake in Boston Scientific in the first quarter valued at approximately $1,076,000. Cetera Investment Advisers grew its position in Boston Scientific by 24.0% in the first quarter. Cetera Investment Advisers now owns 28,793 shares of the medical equipment provider’s stock valued at $1,275,000 after acquiring an additional 5,581 shares in the last quarter. Finally, Sequoia Financial Advisors LLC acquired a new stake in Boston Scientific in the first quarter valued at approximately $230,000. Institutional investors and hedge funds own 90.23% of the company’s stock.

Boston Scientific Price Performance

Shares of BSX opened at $53.64 on Friday. The firm has a market capitalization of $75.10 billion, a price-to-earnings ratio of 90.92, a price-to-earnings-growth ratio of 2.39 and a beta of 0.80. The company has a debt-to-equity ratio of 0.47, a quick ratio of 0.89 and a current ratio of 1.40. Boston Scientific Co. has a one year low of $34.98 and a one year high of $54.08. The stock’s fifty day moving average is $50.95 and its 200-day moving average is $47.54.

Boston Scientific (NYSE:BSX – Get Rating) last issued its quarterly earnings results on Wednesday, April 26th. The medical equipment provider reported $0.47 EPS for the quarter, beating analysts’ consensus estimates of $0.43 by $0.04. The company had revenue of $3.39 billion for the quarter, compared to analyst estimates of $3.16 billion. Boston Scientific had a return on equity of 14.57% and a net margin of 6.91%. The company’s quarterly revenue was up 12.0% compared to the same quarter last year. During the same period last year, the company earned $0.39 earnings per share. Equities analysts anticipate that Boston Scientific Co. will post 1.95 EPS for the current year.

Insider Buying and Selling

In related news, EVP Joseph Michael Fitzgerald sold 63,339 shares of Boston Scientific stock in a transaction dated Tuesday, May 16th. The stock was sold at an average price of $53.60, for a total transaction of $3,394,970.40. Following the transaction, the executive vice president now directly owns 213,859 shares of the company’s stock, valued at $11,462,842.40. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. In related news, EVP Eric Francis Yves Thepaut sold 83,401 shares of the stock in a transaction on Tuesday, May 2nd. The stock was sold at an average price of $52.49, for a total value of $4,377,718.49. Following the completion of the transaction, the executive vice president now owns 12,269 shares in the company, valued at approximately $643,999.81. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Joseph Michael Fitzgerald sold 63,339 shares of the stock in a transaction on Tuesday, May 16th. The shares were sold at an average price of $53.60, for a total value of $3,394,970.40. Following the completion of the transaction, the executive vice president now owns 213,859 shares of the company’s stock, valued at approximately $11,462,842.40. The disclosure for this sale can be found here. Insiders have sold a total of 259,627 shares of company stock valued at $13,157,519 over the last three months. Company insiders own 0.71% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on the stock. Argus increased their price objective on shares of Boston Scientific from $50.00 to $55.00 in a research report on Friday, February 17th. StockNews.com began coverage on shares of Boston Scientific in a research report on Thursday. They issued a “buy” rating for the company. Deutsche Bank Aktiengesellschaft increased their target price on Boston Scientific from $45.00 to $55.00 in a research note on Thursday, April 27th. Truist Financial increased their target price on Boston Scientific from $54.00 to $59.00 and gave the company a “buy” rating in a research note on Monday, April 17th. Finally, BTIG Research increased their target price on Boston Scientific from $53.00 to $54.00 and gave the company a “buy” rating in a research note on Monday, April 17th. One investment analyst has rated the stock with a hold rating, fourteen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and a consensus target price of $53.89.

Boston Scientific Company Profile

(Get Rating)

Boston Scientific Corp. engages in the development, manufacture and marketing of medical devices that are used in interventional medical procedures. It operates through the MedSurg and Cardiovascular segments. The MedSurg segment includes Urology and Neuromodulation. The Cardiovascular segment consists of Cardiology and Peripheral Interventions.